Research Topics
| Michael S RitsnerSummaryAffiliation: Sha'ar Menashe Mental Health Center Country: Israel Publications
| Collaborators |
Detail Information
Publications
Subjective response to antipsychotics of schizophrenia patients treated in routine clinical practice: a naturalistic comparative studyMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
J Clin Psychopharmacol 24:245-54. 2004..Satisfaction with medication together with subjective tolerability needs to be considered in clinical trials...
Predicting domain-specific insight of schizophrenia patients from symptomatology, multiple neurocognitive functions, and personality related traitsMichael S Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
Psychiatry Res 149:59-69. 2007..The findings enable better understanding of the multifactorial nature of insight and highlight targets for more effective intervention and rehabilitation...
Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative studyMichael Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
J Clin Psychopharmacol 24:582-91. 2004....
Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker?Michael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Psychiatry Res 128:219-28. 2004....
Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophreniaMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer, 38814 Hadera, Israel
Neuropsychopharmacology 30:1913-22. 2005..Thus, these data provide evidence that elevated serum cortisol and cortisol/DHEA(S) ratios may serve as markers of biological mechanisms that are involved in responsivity of schizophrenia patients to antipsychotic treatment...
Condensed version of the Quality of Life Scale for schizophrenia for use in outcome studiesMichael Ritsner
Pathological Behavior and Psychobiology Research Laboratory, Sha ar Menashe Mental Health Center, Hadera, Israel
Psychiatry Res 135:65-75. 2005..Utilization of the revised QLS(5) in routine care and clinical trials may potentially facilitate evaluation of treatment outcomes in schizophrenia...
Differences in blood pregnenolone and dehydroepiandrosterone levels between schizophrenia patients and healthy subjectsMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Eur Neuropsychopharmacol 17:358-65. 2007..The neurosteroid levels were monitored for two months and the relationship of these neurosteroids with schizophrenic symptomatology, emotional distress, and anxiety was examined...
Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patientsMichael Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
Qual Life Res 14:1693-703. 2005..Thus, Q-LES-Q-18, a brief, self-administered questionnaire may aid in monitoring quality of life outcomes of schizophrenia, schizoaffective, and mood disorder patients...
Coping patterns as a valid presentation of the diversity of coping responses in schizophrenia patientsMichael S Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
Psychiatry Res 144:139-52. 2006..Coping patterns may be considered an important source of knowledge for patients who struggle with the illness and for mental health professionals who work with schizophrenia patients...
Determinants of changes in perceived quality of life in the course of schizophreniaMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer, 38814, Hadera, Israel
Qual Life Res 15:515-26. 2006....
The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizersMichael S Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
Prog Neuropsychopharmacol Biol Psychiatry 30:1442-52. 2006....
Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trialMichael S Ritsner
Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
J Clin Psychopharmacol 26:495-9. 2006..In this study, the intention was to investigate the efficacy and safety of DHEA administration to ongoing antipsychotic medication in a multicenter, 12-week, double-blind, randomized, placebo-controlled, crossover trial...
Predicting quality of life impairment in chronic schizophrenia from cognitive variablesMichael S Ritsner
The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Qual Life Res 16:929-37. 2007..The aim of this study was to see whether and how cognition deficit predicts quality of life impairments in schizophrenia patients...
The effectiveness of ziprasidone in treating impaired quality of life in schizophrenia: a 12-month, open-label, flexible-dose, naturalistic observational study of patients undergoing usual careMichael S Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Prog Neuropsychopharmacol Biol Psychiatry 31:1470-7. 2007..This long-term observational study examined ziprasidone-induced improvement in satisfaction with HRQL in schizophrenia patients treated under real-world conditions...
Positive family history is associated with persistent elevated emotional distress in schizophrenia: evidence from a 16-month follow-up studyMichael S Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
Psychiatry Res 153:217-23. 2007....
State and trait related predictors of serum cortisol to DHEA(S) molar ratios and hormone concentrations in schizophrenia patientsMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel The Rappaport Faculty of Medicine, Technion, Haifa, Israel
Eur Neuropsychopharmacol 17:257-64. 2007..The present study aimed to examine the contribution of anxiety, and severity of symptoms to the prediction of serum cortisol, DHEA(S) levels and two molar ratios across three examinations...
Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEAMichael S Ritsner
The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Sha ar Menashe Mental Health Center, Hadera, Israel
J Psychiatr Res 44:75-80. 2010....
Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorders: I. Predictive value of disorder-related factorsMichael S Ritsner
Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Qual Life Res 21:837-47. 2012..To provide data on long-term health-related quality of life (HRQL) outcomes among patients with schizophrenia (SZ) and schizoaffective (SA) disorders and determine the predictive value of disorder-related factors...
The long-term changes in coping strategies in schizophrenia: temporal coping typesMichael S Ritsner
Sha'ar Menashe Mental Health Center, Hadera, Israel
J Nerv Ment Dis 194:261-7. 2006..The findings underscore the clinical relevance of temporal coping types and corroborate the appropriateness of focusing on aspects of coping behavior in treatment and rehabilitation of schizophrenia patients...
Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trialAnatoly Gibel
Sha ar Menashe Mental Health Center, Hadera, Israel
Clin Neuropharmacol 31:204-20. 2008..Two questions were addressed in the present report: whether cognitive improvement would occur during 12-month ziprasidone treatment and whether the changes in cognitive functioning are dependent of changes in the illness-related variables...
L-theanine relieves positive, activation, and anxiety symptoms in patients with schizophrenia and schizoaffective disorder: an 8-week, randomized, double-blind, placebo-controlled, 2-center studyMichael S Ritsner
Department of Psychiatry, The Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa, Israel
J Clin Psychiatry 72:34-42. 2011..This is a first study designed to evaluate the efficacy and tolerability of L-theanine augmentation of antipsychotic treatment of patients with chronic schizophrenia and schizoaffective disorder...
Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trialMichael S Ritsner
Department of Psychiatry, The Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
J Clin Psychiatry 71:1351-62. 2010..We investigated the influence of PREG and DHEA on psychotic symptoms and cognitive functioning as an add-on to ongoing antipsychotic treatment of patients with chronic schizophrenia or schizoaffective disorder...
Effectiveness, safety, and tolerability of ziprasidone for treating schizophrenia patients undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trialYael Ratner
Acute Department, Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
Prog Neuropsychopharmacol Biol Psychiatry 31:1401-9. 2007....
Alterations in DHEA metabolism in schizophrenia: two-month case-control studyMichael Ritsner
Acute Department and Clinical Psychobiology Laboratory, Sha ar Menashe Mental Health Center, Mobile Post Hefer, Hadera, Israel
Eur Neuropsychopharmacol 16:137-46. 2006....
Predictors of quality of life in major psychoses: a naturalistic follow-up studyMichael Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
J Clin Psychiatry 64:308-15. 2003..We sought to determine predictors of perceived QOL and to explore the changes that occur regarding QOL among individuals with schizophrenia as compared to patients with schizoaffective/mood disorders...
Perceived quality of life in schizophrenia: relationships to sleep qualityMichael Ritsner
Sha ar Menashe Mental Health Center, Hadera, Israel
Qual Life Res 13:783-91. 2004..Thus, poor QOL reported by schizophrenia patients is substantially associated with poor sleep quality. This association appears both independently and synergistically with depression, distress and side effects of medications...
Anhedonia is an important factor of health-related quality-of-life deficit in schizophrenia and schizoaffective disorderMichael S Ritsner
Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
J Nerv Ment Dis 199:845-53. 2011..Therefore, physical and social hedonic deficits significantly associated with poor HRQL independent of the adverse effects and psychopathological symptoms of SZ/SA. Physical anhedonia may be a predictor for quality-of-life deficit...
Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patientsMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer, Hadera, Israel
Eur Neuropsychopharmacol 14:267-73. 2004....
The detection of neurocognitive decline in schizophrenia using the Mindstreams Computerized Cognitive Test BatteryMichael S Ritsner
Cognitive and Psychobiology Research Laboratory, Sha'ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
Schizophr Res 82:39-49. 2006....
Predicting changes in domain-specific quality of life of schizophrenia patientsMichael Ritsner
Sha'ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
J Nerv Ment Dis 191:287-94. 2003..Changes in stress process-related factors are stronger predictors of fluctuations in QOL domains than changes in illness symptoms and should be considered when evaluating life satisfaction...
Satisfaction with quality of life varies with temperament types of patients with schizophreniaMichael Ritsner
Sha'ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
J Nerv Ment Dis 191:668-74. 2003..Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL...
Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trialsMichael S Ritsner
Psychiatry Department, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Israel
CNS Neurosci Ther 16:32-44. 2010..This review also provides substantial information about clinical trials with DHEA and PREG augmentation with of antipsychotic agents in schizophrenia...
Life satisfaction and suicidal attempts among persons with schizophreniaAlexander M Ponizovsky
Sha-ar Menashe Mental Health Center, Hadera, Israel
Compr Psychiatry 44:442-7. 2003..Clinicians should include QOL in the evaluation of patients with schizophrenia that are suspected to be suicidal...
Age differences in stress process of recent immigrantsMichael Ritsner
Sha'ar Menashe Mental Health Center, Hadera, Israel
Compr Psychiatry 44:135-41. 2003..Thus, age differences in the stress process of recent immigrants are associated with age-specific perceived adjustment difficulties and demographic characteristics...
The attribution of somatization in schizophrenia patients: a naturalistic follow-up studyMichael Ritsner
Sha ar Menashe Mental Health Center, and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel
J Clin Psychiatry 64:1370-8. 2003..This study aimed to explore the prevalence, correlates, and predictors of somatization among schizophrenia patients...
Factor structure in the Camberwell Assessment of Need-Patient Version: The correlations with dimensions of illness, personality and quality of life of schizophrenia patientsMichael S Ritsner
Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, and Sha ar Menashe Mental Health Center, Hadera, Israel
Psychiatry Clin Neurosci 66:499-507. 2012..These subscales may contribute to research and improve treatment of psychiatric patients...
Ten-year quality of life outcomes among patients with schizophrenia and schizoaffective disorder II. Predictive value of psychosocial factorsMichael S Ritsner
Department of Psychiatry, Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
Qual Life Res 21:1075-84. 2012..To identify psychosocial predictors of change in health-related quality of life among patients with schizophrenia (SZ) and schizoaffective (SA) disorders over a 10-year period...
Decreased platelet peripheral-type benzodiazepine receptors in persistently violent schizophrenia patientsMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Israel
J Psychiatr Res 37:549-56. 2003....
The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic studyMichael Ritsner
Institute for Psychiatric Studies, Sha ar Menashe Mental Health Center, Hadera, Israel
Eur Neuropsychopharmacol 12:31-8. 2002..Patient's subjective response to these events rather than their number is more predictive of QOL...
Quality of life and temperament factors in schizophrenia: comparative study of patients, their siblings and controlsRena Kurs
Sha ar Meashe Mental Health Centre, Mobile Post Hefer 38814, Israel
Qual Life Res 14:433-40. 2005..These and other non-illness related factors should be considered when evaluating quality of life outcomes in intervention studies...
Familiality in a five-factor model of schizophrenia psychopathology: findings from a 16-month follow-up studyMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
Psychiatry Res 136:173-9. 2005..It is suggested that dysphoric mood may be a useful phenotype for molecular genetic studies of schizophrenia with positive family history...
Association study of CAG repeats in the KCNN3 gene in Israeli patients with major psychosisMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
Psychiatr Genet 13:143-50. 2003..We investigated the contribution of the CAG repeat at the KCNN3 gene, localized to chromosome 1q21.3, to the genetic susceptibility for schizophrenia, schizoaffective and bipolar disorders...
Neural network identification of high-risk suicide patientsIlan Modai
Sh ar Menashe Mental Health Center, Institute of Psychiatric Studies, Hadera, Israel
Med Inform Internet Med 27:39-47. 2002..Backpropagation (BP) neural networks (NN) successfully detected patient files of patients who had committed MSSA but failed to identify MSSA patients when trained with data collected during face-to-face interviews...
An association of CAG repeats at the KCNN3 locus with symptom dimensions of schizophreniaMichael Ritsner
Sha ar Menashe Mental Health Center, Mobile Post Hefer 38814, Hadera, Israel
Biol Psychiatry 51:788-94. 2002..There has been no attempt to replicate the results. In this study, we investigated whether a symptom polymorphism of schizophrenia is associated with both the CAG repeat numbers and the difference in allele sizes...
Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress InventoryMichael Ritsner
Institute for Psychiatric Studies, Sha'ar Menashe Mental Health Center, Hadera, Israel
Compr Psychiatry 43:229-34. 2002....
Patterns of loneliness in an immigrant populationAlexander M Ponizovsky
Mental Health Services, Department of Research and Planning, Ministry of Health, Jerusalem, Israel
Compr Psychiatry 45:408-14. 2004..An important implication of this study in mental health practice is the sensitivity to these differences when treating recent immigrants...
Bexarotene as add-on to antipsychotic treatment in schizophrenia patients: a pilot open-label trialVladimir Lerner
Division of Psychiatry, Ministry of Health Mental Health Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Be er Sheva, Israel
Clin Neuropharmacol 31:25-33. 2008..This study is the first to investigate the safety and efficacy of add-on oral bexarotene to ongoing antipsychotic treatment in chronic schizophrenia patients who were stabilized on regular antipsychotic treatment...
Hormonal response to dehydroepiandrosterone administration in schizophrenia: findings from a randomized, double-blind, placebo-controlled, crossover studyRael David Strous
J Clin Psychopharmacol 28:456-9. 2008
